Researchers have mapped 180 distinct areas in our brain’s outer mantle, or cortex—more than twice the number previously known.

A new drug developed by scientists at NIAAA limits the progression of liver fibrosis in mice, a hopeful advance against a condition for which there is no current treatment and that often leads to serious liver disease.

NIH-supported research has identified brain patterns in humans that appear to underlie “resilient coping,” the healthy emotional and behavioral responses to stress that help some people handle stressful situations better than others.

Analysis of a trial that used the drug canagliflozin found that as people lost weight, their appetite increased proportionately, leading to consumption of more calories and weight loss plateau (leveling off).

Most women who used an experimental vaginal ring for HIV prevention during the ASPIRE study report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear.

Scientists at NIH have identified a genetic explanation for a syndrome characterized by multiple vexing and difficult-to-treat symptoms.

A 2-year clinical trial that compared 3 drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea than for those receiving Avastin, but only among participants starting treatment with 20/50 or worse vision.

A ring that continuously and safely releases an experimental antiretroviral drug in the vagina provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found.

Researchers have discovered that eliminating cells thought to aid tumor growth did not slow or halt the growth of cancer tumors.

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes.